eISSN 2508-3589
pISSN 2508-1926

Table. 2.

Table. 2.

Initial presentations in the three study groups

Group 1 (25)Group 2 (20)Group 3 (16)Totalp-value
Initial BCVA (LogMAR)0.31±0.480.63±0.570.64±0.790.50±0.620.008*
Initial BCVA over 0.5 (decimal)19 (76.0)9 (45.0)7 (43.8)35 (57.4)0.060
Tumor base (mm)3.69±1.729.61±1.7713.43±1.508.42±4.34< 0.001*
Tumor extension form limbus (mm)2.03±1.929.29±1.7315.61±2.548.28±5.88< 0.001*
Tumor height (mm)3.06±2.139.24±3.308.93±2.256.87±3.91< 0.001*
Involved clock hours1.33±0.512.08±0.712.47±6.181.89±0.77< 0.001*
Shallow anterior chamber2 (8.0)0 (0.0)0 (0.0)2 (3.3)0.333
Anterior chamber reaction7 (28.0)2 (10.0)0 (0.0)9 (14.8)0.035
Cataract7 (28.0)2 (10.0)3 (18.8)12 (19.7)0.366
Vitreous cell2 (8.0)9 (45.0)7 (43.8)18 (29.5)0.007
Vitreous opacity0 (0.0)1 (5.0)1 (6.3)2 (3.3)0.508
Macular edema1 (4.0)0 (0.0)0 (0.0)1 (1.6)1.000
Retinal detachment0 (0.0)6 (30.0)5 (31.3)11 (18.0)0.003

Values are presented as mean±standard deviation or number (%).

BCVA = best-corrected visual acuity; LogMAR = logarithm of minimal angle of resolution.

Kruskal-Wallis test;

chi-square test;

Fisher’s exact test.

Korean J Ret 2019;4:23-31 https://doi.org/10.21561/jor.2019.4.1.23
© 2019 Korean J Ret